PeptidePedia The community reference

Survodutide (revision 1)

Old revision·09:00, 6 Nov 2024·IncretinIvo

This is an old revision of this page, as it stood at 09:00, 6 Nov 2024, saved by IncretinIvo with the summary create article — compound stub. It may differ substantially from the current revision, and any error it contains may since have been corrected.
Survodutide
Development codeBI 456906
ClassDual glucagon/GLP-1 receptor agonist
RouteSubcutaneous, weekly
StatusPhase 3; not approved
Compound infobox · conventions

Survodutide (development code BI 456906) is an investigational peptide that agonises both the glucagon receptor and the GLP-1 receptor. It is under phase 3 evaluation for obesity and has been studied in metabolic dysfunction-associated steatohepatitis. It is not approved for use in any indication.[1]

Unlike the GIP/GLP-1 pairing of tirzepatide, the glucagon/GLP-1 pairing sets two opposing glycaemic effects against each other deliberately. Glucagon-receptor agonism raises hepatic glucose output and energy expenditure; GLP-1 agonism lowers glucose and food intake. The design intent is to capture the energy-expenditure and hepatic-fat effects of the former while the latter dominates the net glycaemic balance.[1]

References

  1. ^ a b Zimmermann T, Thomas L, Baader-Pagler T, et al. "BI 456906: discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy." Molecular Metabolism 66:101633 (2022). DOI:10.1016/j.molmet.2022.101633. PMID 36372428.
Categories: